| Williams College, BA | |
| Chemistry | |
| Harvard Business School, MBA | |
| Business |
Michael is a General Partner at Flybridge Capital Partners focused on information technology, healthcare and medical technology investments. Among a range of general investment themes, Michael is currently focused on opportunities involving the convergence of healthcare and IT, technology-enabled business services, and technologies that address the physical security and homeland defense markets.
Michael A. Greeley is a General Partner at Flybridge Capital Partners. Michael currently represents the firm on the boards of BlueTarp Financial, TARIS Biomedical, MicroCHIPs, inc., PolyRemedy, Predictive Biosciences, Protein Forest, T2 Biosystems and VidSys and led the firm’s investment in Magen BioSciences. Prior to Flybridge, Michael held senior positions with Polaris Venture Partners, GCC Investments, Wasserstein Perella & Co., Morgan Stanley & Co. and Credit Suisse First Boston. Michael currently serves as Chairman of the New England Venture Capital Association where he served as President from 2005 to 2008. He is also on the investment committee of the Partners Innovation Healthcare Fund, a member of the Executive Business Advisory Council for Mass General Hospital for Children, and a trustee and on the investment committee of the Massachusetts Eye and Ear Infirmary. Michael received a B.A. with honors in Chemistry from Williams College and an M.B.A. from Harvard Business School.
